Milnacipran (savella) for fibromyalgia.
D018759:Adrenergic Uptake Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003071:Cognition / Q000502:physiology; D003521:Cyclopropanes / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D017277:Drug Approval; D004347:Drug Interactions; D005356:Fibromyalgia / Q000188:drug therapy* / Q000523:psychology; D006801:Humans; D000078764:Milnacipran; D018763:Muscle Fatigue / Q000187:drug effects; D010146:Pain / Q000188:drug therapy / Q000209:etiology; D016032:Randomized Controlled Trials as Topic; D014481:United States; D014486:United States Food and Drug Administration
D018759:Adrenergic Uptake Inhibitors; D003521:Cyclopropanes; D000078764:Milnacipran